Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease

Trial Profile

Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Prednisone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Jun 2019.
    • 29 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
    • 29 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top